{
    "root": "34169098-5d19-b138-e063-6294a90a5feb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluocinonide",
    "value": "20250501",
    "ingredients": [
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "DIISOPROPYL ADIPATE",
            "code": "P7E6YFV72X"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "FLUOCINONIDE",
            "code": "2W4A77YPAN"
        }
    ],
    "indications": "fluocinonide topical solution usp , 0.05 % indicated relief inflammatory pruritic manifestations corticosteroid-responsive dermatoses .",
    "contraindications": "fluocinonide topical solution usp , 0.05 % generally applied affected area thin film two four times daily depending severity condition . occlusive dressings may used management psoriasis recalcitrant conditions . infection develops , occlusive dressings discontinued appropriate antimicrobial therapy instituted .",
    "warningsAndPrecautions": "fluocinonide topical solution usp , 0.05 % supplied 20 ml ( ndc 51672-1273-2 ) 60 ml ( ndc 51672-1273-4 ) bottles .",
    "adverseReactions": "topical corticosteroids contraindicated patients history hypersensitivity components preparation .",
    "indications_original": "Fluocinonide Topical Solution USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.",
    "contraindications_original": "Fluocinonide Topical Solution USP, 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.\n                  Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.\n                  If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.",
    "warningsAndPrecautions_original": "Fluocinonide Topical Solution USP, 0.05% is supplied in 20 mL (NDC 51672-1273-2) and 60 mL (NDC 51672-1273-4) bottles.",
    "adverseReactions_original": "Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."
}